Your Search Returned 71 tagged news reports
File this under getting ahead of the curve.' Anticipating that the FDA will approve the Vivus diet pill, at least one law firm is already trolling for possible clients. The Internet ad by the Van Wey law firm actually does not invite anyone to pick
is soaring 36% after agreeing to be taken private by TPG Capital. Par is welcome to seek a better deal until August 24, but I'm reluctant to think Par investors will do much better. The company has a small proprietary products division, but the
Obesity is not just an American epidemic but a global pandemic...The FDA's decision is highly respected globally and facilitates approvals in the rest of the world...Everything that I have read indicates Belviq should get approved in Europe before
I admit I'm now standing on a branch that's 6 inches in diameter and only a foot off the ground, but this is the Food and Drug Administration, after all...The confidence in an approval, from me and most of the rest of the investing world, comes from
My Big Fat FDA Decision Arena now looks like it will be the first to market with Belviq, already having a partnership in place with Eisai Pharmaceutical of Japan to market in the U.S. Approval for the European market is likely to be announced soon.
Reza is a member of The Motley Fool Blog Network -- entries represent the personal opinions of our bloggers and are not formally edited...One would normally assume that if Vivus gets FDA approval for Qnexa the company should be worth more than today
Like the rising-tide-lifts-all-boats theory, the FDA approval yesterday of the Belviq diet pill from Arena Pharmaceuticals prompted investors to run up share prices of two other drugmakers that aspire to sell their own salves for the obese, Vivus and
Qnexa is squarely aimed at the rising obesity rate in both the US and Europe. With an estimated 149 million people in the U.S. overweight or obese, there is no question this is an underserved market for a drug. The international market
Reza is a member of The Motley Fool Blog Network -- entries represent the personal opinions of our bloggers and are not formally edited. It is not often that Main Street gets to beat Wall Street at its own game but it does happen on rare occasions...
Watch stocks you care about The single, easiest way to keep track of all the stocks that matter.....When considering any stock for your portfolio, don't be swayed by just the positives. Examine its pros and cons, and decide whether it's possible